BPC-157 (Body Protection Compound)
BPC-157 (Body Protection Compound) risk profile, scheduling, and guidance for claims professionals and care workers .
BPC-157 (Body Protection Compound) is classified as Low risk (2 risk points) by AllMeds. NOT TGA registered. Used via compounding for injury recovery. Animal studies only. No human clinical trials. Commonly promoted by influencers.
Key Takeaways
- Risk level: Low (2 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | Unscheduled | Not PBS listed |
Risk Profile
NOT TGA registered. Used via compounding for injury recovery. Animal studies only. No human clinical trials. Commonly promoted by influencers.
Regulatory and Compliance Guidance
When BPC-157 (Body Protection Compound) appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as Unscheduled under the Therapeutic Goods Administration (TGA).
Clinical Evidence
- Huberman Lab: Peptides for Health, Performance & Longevity (2023)
Huberman discusses BPC-157 as a tissue repair peptide. Notes animal-only evidence. Mentions personal use. Episode widely cited by patients requesting BPC-157.
Neuroscience professor but speaking outside expertise. Massive audience influence on patient demand.
- WADA Prohibited List — Peptide Hormones and Growth Factors (2024)
BPC-157 is banned by WADA under S2 Peptide Hormones. Relevant for workers comp claimants in occupations with anti-doping requirements.
International regulatory body for sport
- TGA: Peptides Not Registered for Therapeutic Use in Australia (2023)
TGA has warned that peptides like BPC-157 obtained from compounding pharmacies or online are not TGA-registered and quality cannot be guaranteed.
Australian regulatory authority
- BPC 157: A Review of its Regenerative and Protective Properties — Systematic Review (2022)
Systematic review of BPC-157 literature. All studies are animal models (rats). Shows wound healing, tendon repair, GI protection in rodents. No human clinical trials exist.
Peer-reviewed but only animal data — no human evidence
- FDA Warning: BPC-157 Not Approved for Human Use (2024)
FDA has issued multiple warning letters to companies selling BPC-157 as a research chemical for human consumption. Not approved as a drug.
Federal regulatory authority — definitive on approval status
- r/Peptides — BPC-157 Experience Megathread (2024)
Large community of self-experimenters sharing dosing protocols, sources, and anecdotal results. No clinical oversight. Supply chain quality unknown.
Anecdotal only — no verified outcomes, significant selection and reporting bias
- Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (2021)
Review by the original BPC-157 research group (Sikiric lab, Zagreb). Describes potential mechanisms. Note: same research group has authored most BPC-157 papers.
Published in peer-reviewed journal but potential conflict — most BPC-157 papers come from one lab
Need to assess this medication across your caseload?
Run a full risk assessment including BPC-157 (Body Protection Compound) interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.